Across TCGA pan-cancer cohorts, IGBP1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGBP1 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher IGBP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGBP1 expression acts as an unfavorable survival marker.
COAD, SKCM, and READ are the cancer types where IGBP1 Mutation most reproducibly stratifies survival.